CVS stock undervalued due to regulatory headwinds

PARAGRAPH 1 --- What happened: CVS Health's stock price declined earlier this year following reports of a meager 0.09% Medicare payment rate increase for next year. However, the company's shares rebounded after Medicare's final ruling announced a 2.5% escalation. On March 25, UBS analyst Kevin Caliendo reiterated a 'Buy' rating and $97 price target on CVS, citing its proposed settlement with the Federal Trade Commission and core strengths.

PARAGRAPH 2 --- Market impact: This narrative affects healthcare stocks, particularly pharmacy benefit managers like CVS. The regulatory clarity and higher Medicare payment rates drive the sector's valuation repricing, benefiting CVS and peers. CVS is now cheaper than its peers, presenting an attractive investment opportunity.

PARAGRAPH 3 --- What to watch next: Investors should monitor CVS's Q1 earnings release on April 28, which will provide insights into the company's performance amidst regulatory changes. Additionally, the finalization of CVS's proposed settlement with the FTC, expected in Q2, could further boost the stock's price. Lastly, keep an eye on Medicare's future payment rate announcements, as they significantly impact CVS's revenue.